Buttmann M - Search Results

1

Assessment of microRNA-related SNP effects in the 3' untranslated region of the IL22RA2 risk locus in multiple sclerosis.

Lill CM, Schilling M, Ansaloni S, Schröder J, Jaedicke M, Luessi F, Schjeide BM, Mashychev A, Graetz C, Akkad DA, Gerdes LA, Kroner A, Blaschke P, Hoffjan S, Winkelmann A, Dörner T, Rieckmann P, Steinhagen-Thiessen E, Lindenberger U, Chan A, Hartung HP, Aktas O, Lohse P, Buttmann M, Kümpfel T, Kubisch C, Zettl UK, Epplen JT, Zipp F, Bertram L. Lill CM, et al. Among authors: buttmann m. Neurogenetics. 2014 May;15(2):129-34. doi: 10.1007/s10048-014-0396-y. Epub 2014 Mar 18. Neurogenetics. 2014. PMID: 24638856

2

Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study.

O'Connor P, Comi G, Montalban X, Antel J, Radue EW, de Vera A, Pohlmann H, Kappos L; FTY720 D2201 Study Group. O'Connor P, et al. Neurology. 2009 Jan 6;72(1):73-9. doi: 10.1212/01.wnl.0000338569.32367.3d. Neurology. 2009. PMID: 19122034 Clinical Trial.

3

Local pain during REBIF injection is not due to acidic pH.

Buttmann M, Goebeler M, Rieckmann P. Buttmann M, et al. J Neurol Neurosurg Psychiatry. 2004 Jul;75(7):1078. doi: 10.1136/jnnp.2003.025114. J Neurol Neurosurg Psychiatry. 2004. PMID: 15201384 Free PMC article. No abstract available.

4

Interferon-beta induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis.

Buttmann M, Merzyn C, Rieckmann P. Buttmann M, et al. J Neuroimmunol. 2004 Nov;156(1-2):195-203. doi: 10.1016/j.jneuroim.2004.07.016. J Neuroimmunol. 2004. PMID: 15465611

5

Subcutaneous interferon-beta injections in patients with multiple sclerosis initiate inflammatory skin reactions by local chemokine induction.

Buttmann M, Goebeler M, Toksoy A, Schmid S, Graf W, Berberich-Siebelt F, Rieckmann P. Buttmann M, et al. J Neuroimmunol. 2005 Nov;168(1-2):175-82. doi: 10.1016/j.jneuroim.2005.07.011. Epub 2005 Aug 26. J Neuroimmunol. 2005. PMID: 16126281 Clinical Trial.

6

Interferon-beta is a potent inducer of interferon regulatory factor-1/2-dependent IP-10/CXCL10 expression in primary human endothelial cells.

Buttmann M, Berberich-Siebelt F, Serfling E, Rieckmann P. Buttmann M, et al. J Vasc Res. 2007;44(1):51-60. doi: 10.1159/000097977. Epub 2006 Dec 13. J Vasc Res. 2007. PMID: 17167270

7

Interferon-beta1b in multiple sclerosis.

Buttmann M, Rieckmann P. Buttmann M, et al. Expert Rev Neurother. 2007 Mar;7(3):227-39. doi: 10.1586/14737175.7.3.227. Expert Rev Neurother. 2007. PMID: 17341170 Review.

8

Atorvastatin partially prevents an inflammatory barrier breakdown of cultured human brain endothelial cells at a pharmacologically relevant concentration.

Buttmann M, Lorenz A, Weishaupt A, Rieckmann P. Buttmann M, et al. J Neurochem. 2007 Aug;102(4):1001-8. doi: 10.1111/j.1471-4159.2007.04563.x. Epub 2007 Apr 17. J Neurochem. 2007. PMID: 17442054 Free article.

9

TRAIL, CXCL10 and CCL2 plasma levels during long-term Interferon-beta treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response.

Buttmann M, Merzyn C, Hofstetter HH, Rieckmann P. Buttmann M, et al. J Neuroimmunol. 2007 Oct;190(1-2):170-6. doi: 10.1016/j.jneuroim.2007.08.009. Epub 2007 Sep 19. J Neuroimmunol. 2007. PMID: 17884184 Clinical Trial.

10

Treating multiple sclerosis with monoclonal antibodies.

Buttmann M, Rieckmann P. Buttmann M, et al. Expert Rev Neurother. 2008 Mar;8(3):433-55. doi: 10.1586/14737175.8.3.433. Expert Rev Neurother. 2008. PMID: 18345973 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

90 results

Search Page

Filters